New Objective and McKinley Scientific Announce a Strategic Co-Marketing Collaboration
News Nov 30, 2012
McKinley Scientific, LLC and New Objective, Inc. have announced that they have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for delivery of high-performance LC-MS systems.
This includes the financing and support services for mass spectrometry provided by McKinley Scientific and New Objective's industry-recognized nanospray front-end technologies.
Together, the firms intend to co-market their products through industry publications and trade shows, and the development of distribution and services to deliver high-end MS solutions.
Paul Corcoran, President and CEO of McKinley Scientific commented that: "New Objective and McKinley Scientific have enjoyed a close relationship for many years. It was a natural progression for us to combine our collective strengths into a mutually beneficial relationship. Our combined customer focus will yield broader and more powerful solutions with expanded choices, adaptability, and education opportunities. We are very excited to support Dr. Valaskovic along with the wonderful products and people at New Objective."
Dr. Gary Valaskovic, the co-founder and President of New Objective adds: "I am very pleased to have strengthened and formalized the excellent, long standing relationship between New Objective and McKinley Scientific. Paul Corcoran and McKinley are an outstanding team of individuals dedicated to transforming the business of mass spectrometry and related technologies in the life science marketplace. The combination of New Objective¹s world class front-end hardware and consumables, with the outstanding finance, sales, and support structure of McKinley Scientific is a winning combination for the customer, one that will enable the development of new markets for both organizations."
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018
18th International Conference and Exhibition on Analytical & Bioanalytical Chromatographic Techniques
Nov 02 - Nov 03, 2017